|
Fig. 5
SCD inhibitors repress the pro-tumor and drug-resistant properties of SCDhigh CAFs
(A) Maximal tolerance dose (MTD) of three SCD inhibitors (MK-8245, MF-438, and Aramchol) for 60 hpf zebrafish larvae.
(B) Representative images of immune staining of MET, KRAS, HRAS, ACTA2, CXCR5, and COL6A2 in the PDAC tissues from patient #2.
(C) Representative confocal fluorescent images of the lateral views of the zPDX models xenografted by PDAC #2 (Red) mixed with CAFs from patient #2 or #7 (Green) treated by GEM, DDP with or without the administration of the SCD inhibitor aramchol.
(D) Statistics of the fluorescence intensity of the PDAC cells in chemotherapy-treated zPDX models with or without all three SCD inhibitors.
(E) Schematic diagram of the CAF-derived unsaturated fatty acids contributing to the drug resistance of PDACs against DDP and GEM.
(F) Application of the “chemotherapy PLUS” protocol to fast predict the therapeutic efficacy of novel target inhibitors using zPDX models. Scale bar: 50 μm. p < 0.05 was considered significant.